Paul W. Crawford
Experienced in Lactic Acidosis

Dr. Paul W. Crawford

Nephrology
9730 S Western Ave, Suite 326, 
Evergreen Park, IL 
Accepting New Patients
Offers Telehealth
Experienced in Lactic Acidosis
9730 S Western Ave, Suite 326, 
Evergreen Park, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Paul Crawford is a Nephrologist in Evergreen Park, Illinois. Dr. Crawford is rated as an Experienced provider by MediFind in the treatment of Lactic Acidosis. His top areas of expertise are Chronic Kidney Disease, End-Stage Renal Disease (ESRD), Nephrosclerosis, and Renovascular Hypertension. Dr. Crawford is currently accepting new patients.

His clinical research consists of co-authoring 5 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Nephrology
Licenses
Internal Medicine in IL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

9730 S Western Ave, Suite 326, Evergreen Park, IL 60805

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases
Enrollment Status: Completed
Publish Date: June 03, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Multi-Center, Randomized, Two-Cohort Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of CTAP101 (Calcifediol) Extended-Release Capsules to Treat Secondary Hyperparathyroidism in Subjects With Vitamin D Insufficiency and Chronic Kidney Disease Requiring Regular Hemodialysis.
A Multi-Center, Randomized, Two-Cohort Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of CTAP101 (Calcifediol) Extended-Release Capsules to Treat Secondary Hyperparathyroidism in Subjects With Vitamin D Insufficiency and Chronic Kidney Disease Requiring Regular Hemodialysis.
Enrollment Status: Terminated
Publish Date: March 30, 2025
Intervention Type: Drug
Study Drug: Calcifediol
Study Phase: Phase 2
A Double-Blind, Double Dummy, Randomized, Phase 1b, Nitrofurantoin Controlled, Repeat Oral Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Microbiological Response of GSK3882347 in Female Participants With Acute Uncomplicated Urinary Tract Infection
A Double-Blind, Double Dummy, Randomized, Phase 1b, Nitrofurantoin Controlled, Repeat Oral Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Microbiological Response of GSK3882347 in Female Participants With Acute Uncomplicated Urinary Tract Infection
Enrollment Status: Completed
Publish Date: January 28, 2025
Intervention Type: Drug
Study Drugs: GSK3882347, Nitrofurantoin
Study Phase: Phase 1
A Phase 3 Randomized, Open-label (Sponsor-blind), Active-controlled, Parallel-group, Multi-center, Event Driven Study in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease to Evaluate the Safety and Efficacy of Daprodustat Compared to Darbepoetin Alfa
A Phase 3 Randomized, Open-label (Sponsor-blind), Active-controlled, Parallel-group, Multi-center, Event Driven Study in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease to Evaluate the Safety and Efficacy of Daprodustat Compared to Darbepoetin Alfa
Enrollment Status: Completed
Publish Date: April 02, 2024
Intervention Type: Drug
Study Drugs: Daprodustat, Darbepoetin Alpha
Study Phase: Phase 3
An Open-Label, Repeated-Dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Oral CTAP101 Capsules, Immediate- Release (IR) Calcifediol, High-Dose Cholecalciferol, and Paricalcitol Plus Low-Dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency
An Open-Label, Repeated-Dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Oral CTAP101 Capsules, Immediate- Release (IR) Calcifediol, High-Dose Cholecalciferol, and Paricalcitol Plus Low-Dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency
Enrollment Status: Completed
Publish Date: December 09, 2022
Intervention Type: Drug
Study Phase: Phase 4
A Multi-Center Open-label Investigation to Assess the Safety and Efficacy of Multiple Doses of DM199 in Patients With Chronic Kidney Disease
A Multi-Center Open-label Investigation to Assess the Safety and Efficacy of Multiple Doses of DM199 in Patients With Chronic Kidney Disease
Enrollment Status: Completed
Publish Date: March 31, 2022
Intervention Type: Drug
Study Drug: DM199
Study Phase: Phase 2
A Randomized, Open-label Study to Evaluate the Effect of Daprodustat on Blood Pressure in Subjects With Anemia Associated With Chronic Kidney Disease on Hemodialysis Switched From a Stable Dose of an Erythropoiesis-stimulating Agent
A Randomized, Open-label Study to Evaluate the Effect of Daprodustat on Blood Pressure in Subjects With Anemia Associated With Chronic Kidney Disease on Hemodialysis Switched From a Stable Dose of an Erythropoiesis-stimulating Agent
Enrollment Status: Completed
Publish Date: June 03, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

5 Total Publications

Navigating variants of uncertain significance in genetic dyslipidemia: how to assess and counsel patients.
Navigating variants of uncertain significance in genetic dyslipidemia: how to assess and counsel patients.
Journal: Current opinion in lipidology
Published: February 14, 2025
Similar Doctors
Advanced in Lactic Acidosis
Dr. Naila I. Ahmed
Nephrology
Advanced in Lactic Acidosis
Dr. Naila I. Ahmed
Nephrology

Nephrology Associates Of Northern Illinois Ltd

3223 W 63rd St, Lawn Terr Nephrology Assc, 
Chicago, IL 
 (4.5 miles away)
773-735-4884
Languages Spoken:
English, Bengali, Hindi, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Naila Ahmed is a Nephrologist in Chicago, Illinois. Dr. Ahmed is rated as a Distinguished provider by MediFind in the treatment of Lactic Acidosis. Her top areas of expertise are Chronic Kidney Disease, Acute Kidney Failure, End-Stage Renal Disease (ESRD), and Low Sodium Level. Dr. Ahmed is currently accepting new patients.

Advanced in Lactic Acidosis
Dr. Zdzislawa T. Majka-Kravets
Nephrology
Advanced in Lactic Acidosis
Dr. Zdzislawa T. Majka-Kravets
Nephrology
3100 Theodore Street, Suite 201, 
Joliet, IL 
 (27.1 miles away)
815-744-5550
Languages Spoken:
English, Polish, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Zdzislawa Majka-Kravets is a Nephrologist in Joliet, Illinois. Dr. Majka-Kravets is rated as a Distinguished provider by MediFind in the treatment of Lactic Acidosis. Her top areas of expertise are Chronic Kidney Disease, End-Stage Renal Disease (ESRD), Acute Kidney Failure, Low Sodium Level, and Endoscopy. Dr. Majka-Kravets is currently accepting new patients.

Advanced in Lactic Acidosis
Dr. Ernest F. Dejesus
Nephrology
Advanced in Lactic Acidosis
Dr. Ernest F. Dejesus
Nephrology

Nani-Ihp LLC

133 E Brush Hill Rd, 
Elmhurst, IL 
 (16.6 miles away)
630-832-2183
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ernest Dejesus is a Nephrologist in Elmhurst, Illinois. Dr. Dejesus is rated as a Distinguished provider by MediFind in the treatment of Lactic Acidosis. His top areas of expertise are Acute Kidney Failure, End-Stage Renal Disease (ESRD), Low Sodium Level, and Chronic Kidney Disease. Dr. Dejesus is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Crawford's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile